Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer

被引:33
作者
Simi, L
Venturini, G
Malentacchi, F
Gelmini, S
Andreani, M
Janni, A
Pastorekova, S
Supuran, CT
Pazzagli, M
Orlando, C [1 ]
机构
[1] Univ Florence, Dept Clin Physiopathol, Clin Biochem & Endocrinol Unit, I-50121 Florence, Italy
[2] Azienda Osped Careggi, Dept Thorac Surg, Florence, Italy
[3] Slovak Acad Sci, Inst Virol, Bratislava, Slovakia
[4] Univ Florence, Lab Bioinorgan Chem, Florence, Italy
关键词
hypoxia; real time RT-PCR; TaqMan probes; immunoblotting;
D O I
10.1016/j.lungcan.2005.11.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hypoxia is associated with malignant progression and poor outcome in human cancers. The effects of hypoxia are mediated by a series of genomic changes that enable tumor cells to survive or escape their oxygen deficient environment. Recent studies indicated that carbonic anhydrase IX (CA IX) is an intrinsic marker of hypoxia. In the present study we investigated with quantitative RT-PCR the expression of CA IX mRNA in 93 non-small cell lung carcinomas (NSCLC) and in their paired not affected tissues. CA IX mRNA was expressed in 100% NSCLC and in 76% of paired not affected tissues, even if tumoral CA IX expression was found constantly higher (p < 0.02) than that found in normal tissues. The increase of CA IX mRNA expression in cancer tissues was significantly correlated to the increase of corresponding protein, as determined with conventional immunoblotting (p = 0.027). In addition the expression of CA IX mRNA in NSCLC samples was significantly correlated to VEGF (p = 0.002) and MMP-9 (p = 0.002) mRNAs. Whereas CA IX mRNA expression was not associated to any clinical-pathological. parameters in our patients, global survival analysis of cancer-related death revealed that high expression of CA IX mRNA predicted unfavorable outcome (p = 0.001) and shorter disease free survival interval (p = 0.004). A multivariate analysis showed that CA IX expression was the strongest prognostic parameter (p = 0.000) in comparison to other conventional predictive markers. In addition, differences emerged on the basis of clinical-pathological parameters: in fact separate Kaplan-Meyer analyses of patients indicated that whereas high levels of CA IX mRNA expression were not predictive of worse prognosis in early NSCLC (G1, T1, Stage 1 and pN- patients), this parameter appeared highly significant in advanced NSCLC (G2-G3, T2-T3, Stage 2-3 and pN+ patients). Finally we demonstrated that CA IX expression was not able to discriminate different survival probability in adenocarcinomas, whereas the same parameter was highly predictive in squamous (p = 0.03) and adenosquamous cell carcinomas (p = 0.001). (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:59 / 66
页数:8
相关论文
共 25 条
[1]  
Bui MHT, 2003, CLIN CANCER RES, V9, P802
[2]  
CHEN F, 1995, CANCER RES, V55, P4804
[3]   Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma [J].
Chia, SK ;
Wykoff, CC ;
Watson, PH ;
Han, C ;
Leek, RD ;
Pastorek, J ;
Gatter, KC ;
Ratcliffe, P ;
Harris, AL .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3660-3668
[4]  
Giatromanolaki A, 2001, CANCER RES, V61, P7992
[5]   Hypoxia - A key regulatory factor in tumour growth [J].
Harris, AL .
NATURE REVIEWS CANCER, 2002, 2 (01) :38-47
[6]  
Hussain SA, 2004, ONCOL REP, V11, P1005
[7]   Transcriptional regulation of the MN/CA 9 gene coding for the tumor-associated carbonic anhydrase IX -: Identification and characterization of a proximal silencer element [J].
Kaluz, S ;
Kaluzová, M ;
Opavsky, R ;
Pastoreková, S ;
Gibadulinová, A ;
Dequiedt, F ;
Kettmann, R ;
Pastorek, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (46) :32588-32595
[8]   Expression of HIF-1α, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer [J].
Kim, SJ ;
Rabbani, ZN ;
Dewhirst, MW ;
Vujaskovic, Z ;
Vollmer, RT ;
Schreiber, EG ;
Oosterwijk, E ;
Kelley, MJ .
LUNG CANCER, 2005, 49 (03) :325-335
[9]   Carbonic anhydrase IX in early-stage non-small cell lung cancer [J].
Kim, SJ ;
Rabbani, ZN ;
Vollmer, RT ;
Schreiber, EG ;
Oosterwijk, E ;
Dewhirst, MW ;
Vujaskovic, Z ;
Kelley, MJ .
CLINICAL CANCER RESEARCH, 2004, 10 (23) :7925-7933
[10]  
Koukourakis MI, 2001, CLIN CANCER RES, V7, P3399